Experience of national TB partnerships
These guidelines for the National Pharmacovigilance and Medicine Information System in Rwanda have been developed to ensure that safe, efficacious and quality medicines are made available to all Rwandans.
PLOS Glob Public Health 4(12): e0004035. https://doi. org/10.1371/journal.pgph.0004035.
A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool-
aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and
elimination program...s. There is now a priority to ensure that the drug reaches all at-risk PSAC
in endemic areas, including hard-to-reach areas and populations. This study aimed to deter-
mine schistosomiasis treatment-related contextual factors among fishermen and island popu-
lations in Homa Bay County, Kenya, and to identify a suitable platform to deliver arPZQ.
more
The Compendium of data and evidence-related tools for use in TB planning and programming was developed as a companion document to the People-centred framework for tuberculosis programme planning and prioritization – user guide, published by the World Health Organization (WHO)... in 2019. The compendium is intended to support implementation of the people-centred framework user guide. It can also be used independently to inform decisions taken by national tuberculosis (TB) programmes about the implementation of the tools included in this document.
more
First WHO Global Ministerial Conference
Ending TB in the Sustainable Development Era: A Multisectoral Response
Moscow, Russian Federation, 16-17 November 2017
Interim practical manual supporting implementation of the WHO guidelines on core components of infection prevention and control programmes
The outbreak of COVID-19 comes with unpredictable primary and secondary impacts on vulnerable and food-insecure populations across the world. Mortality and morbidity appear to be most acute for elderly people, and those with underlying health conditions. At the same time, the widely anti...cipated economic downturn could have a more devastating effect on the world’s poor than the virus itself
more
These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB.
This Ra...pid Communication is released in advance of updated WHO consolidated guidelines expected later in 2022, to inform national TB programmes and other stakeholders of key changes in the treatment of DR-TB and to allow for rapid transition and planning at the country level.
more
In diesem Bericht untersucht der Unabhängige Experte, inwiefern lesbische, schwule, bisexuelle, transgeschlechtliche und diversgeschlechtliche Menschen nach wie vor durch diskriminierende Rechtsvorschriften und soziokulturelle Normen im Bildungswesen, in der Gesundheits-und W...ohnraumversorgung, in der Arbeitswelt sowie in anderen Bereichen marginalisiert und ausgegrenzt werden. Darüber hinaus betrachtet der Unabhängige Experte das Thema Inklusion und den Zugang zu den entsprechenden Rechten unter dem Aspekt der Intersektionalität und analysiert die verstärkende Diskriminierung, die zu Ausgrenzung und Marginalisierung führt.
more
May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... the WHO and the PAHO recommend the use of corticosteroids, tocilizumab, baricitinib, and casirivimab e imdevimab (the latter in seronegative COVID-19 patients) and propose the use of sotrovimab, casirivimab/imdevimab, and molnupiravir in patients with non-severe illness who are at high risk for complications
more